5-HT2A Agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “5-HT2A Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT2A Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
5-HT2A Agonists: Overview
The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor. 5-HT is short for 5-hydroxy-tryptamine, which is serotonin.
Function - 5-HT2A is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT2A may also have an inhibitory effect on certain areas such as the visual cortex and the orbitofrontal cortex. The 5-HT2A receptor is known primarily to couple to the G?q signal transduction pathway. Upon receptor stimulation with agonist, G?q and ?-? subunits dissociate to initiate downstream effector pathways. G?q stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca2+ release
5-HT2A Agonists -. Activation of the 5-HT2A receptor is necessary for the effects of the 'classic' psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A Agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched. Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Newer findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors. Agonists enhance dopamine in PFC, enhance memory and play an active role in attention and learning.
5-HT2A Agonists Emerging Drugs Chapters
This segment of the 5-HT2A Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
5-HT2A Agonists Emerging Drugs
Further product details are provided in the report……..
5-HT2A Agonists: Therapeutic Assessment
This segment of the report provides insights about the different 5-HT2A Agonists drugs segregated based on following parameters that define the scope of the report, such as:
5-HT2A Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 5-HT2A Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 5-HT2A Agonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “5-HT2A Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT2A Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
5-HT2A Agonists: Overview
The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor. 5-HT is short for 5-hydroxy-tryptamine, which is serotonin.
Function - 5-HT2A is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT2A may also have an inhibitory effect on certain areas such as the visual cortex and the orbitofrontal cortex. The 5-HT2A receptor is known primarily to couple to the G?q signal transduction pathway. Upon receptor stimulation with agonist, G?q and ?-? subunits dissociate to initiate downstream effector pathways. G?q stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca2+ release
5-HT2A Agonists -. Activation of the 5-HT2A receptor is necessary for the effects of the 'classic' psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A Agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched. Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Newer findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors. Agonists enhance dopamine in PFC, enhance memory and play an active role in attention and learning.
5-HT2A Agonists Emerging Drugs Chapters
This segment of the 5-HT2A Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
5-HT2A Agonists Emerging Drugs
- Brilaroxazine : Reviva Biopharmaceuticals
Further product details are provided in the report……..
5-HT2A Agonists: Therapeutic Assessment
This segment of the report provides insights about the different 5-HT2A Agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on 5-HT2A Agonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
5-HT2A Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 5-HT2A Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 5-HT2A Agonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence 5-HT2A Agonists R&D. The therapies under development are focused on novel approaches for 5-HT2A Agonists.
- 5-HT2A Agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing 5-HT2A Agonists drugs?
- How many 5-HT2A Agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for 5-HT2A Agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 5-HT2A Agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for 5-HT2A Agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Reviva Biopharmaceuticals
- CURE Pharmaceutical
- EmpathBio
- Eleusis
- Brilaroxazine
- Lysergide
- EMP 01
- ELE 02
Introduction
Executive Summary
5-HT2A AGONISTS: OVERVIEW
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
5-HT2A AGONISTS – DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
In-depth Commercial Assessment
• 5-HT2A Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
5-HT2A AGONISTS COLLABORATION DEALS
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Brilaroxazine:Reviva Biopharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
ELE 02: Eleusis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
5-HT2A AGONISTS KEY COMPANIES
5-HT2A AGONISTS KEY PRODUCTS
5-HT2A AGONISTS- UNMET NEEDS
5-HT2A AGONISTS- MARKET DRIVERS AND BARRIERS
5-HT2A AGONISTS- FUTURE PERSPECTIVES AND CONCLUSION
5-HT2A AGONISTS ANALYST VIEWS
5-HT2A AGONISTS KEY COMPANIES
Appendix
Executive Summary
5-HT2A AGONISTS: OVERVIEW
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
5-HT2A AGONISTS – DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
In-depth Commercial Assessment
• 5-HT2A Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
5-HT2A AGONISTS COLLABORATION DEALS
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Brilaroxazine:Reviva Biopharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
ELE 02: Eleusis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
5-HT2A AGONISTS KEY COMPANIES
5-HT2A AGONISTS KEY PRODUCTS
5-HT2A AGONISTS- UNMET NEEDS
5-HT2A AGONISTS- MARKET DRIVERS AND BARRIERS
5-HT2A AGONISTS- FUTURE PERSPECTIVES AND CONCLUSION
5-HT2A AGONISTS ANALYST VIEWS
5-HT2A AGONISTS KEY COMPANIES
Appendix
LIST OF TABLES
Table 1 Total Products for 5-HT2A Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for 5-HT2A Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for 5-HT2A Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for 5-HT2A Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
